

REPORT DOCUMENTATION

AD-A229 110

1188
Using data sources,
other aspect of the
BRL 1215 Jefferson
Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

2

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing the data needed, and completing and reviewing the collection of information, including suggestions for reducing this burden, to Washington, DC 20503, Bureau of the Census, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 12 Oct 90		3. REPORT TYPE AND DATES COVERED FINAL 01 May 89 to 30 Apr 90	
4. TITLE AND SUBTITLE EQUIPMENT SUPPORT GRANT FOR AIR FORCE TASK "CHEMICAL DEFENSE DRUGS EFFECTS WITH EXERCISE AND THERMAL STRESS"				5. FUNDING NUMBERS G - AFOSR-89-0318 PF - 61102F PR - 2312 TA - A2	
6. AUTHOR(S) Dr Reynaldo S. Elizondo					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas 203 Administration Building El Paso, TX 79968				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) Dr William O Berry AFOSR/NL Building 410 Bolling AFB, DC 20332				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
<div style="text-align: center;"> <p>DTIC</p> <p>ELECTE</p> <p>NOV 16 1990</p> <p>S B D</p> </div>					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; Distribution unlimited.				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The Equipment Support Grant, provided the funds for the acquisition at the University of Texas at El Paso of a Nor-Lake Enviro-line Walk-in Climatic Chamber (6' long, 8' wide and 9' high) at a cost of \$10,809.00. The freight charges were \$977.00. The grant also provided resources for the renovation of laboratory space and installation costs totalling \$8214.00. The acquisition and installation of the above equipment supported a series of studies designed to quantitate the effects of neuroactive agents such as atropine and pyridostigmine on numerous physiological and performance parameters in a primate animal model which could not be carried out without the equipment support from this grant.					
<div style="text-align: center;"> <p>DISTRIBUTION STATEMENT A</p> <p>Approved for public release</p> <p>Distribution Unlimited</p> </div>					
14. SUBJECT TERMS				15. NUMBER OF PAGES	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT (U)		18. SECURITY CLASSIFICATION OF THIS PAGE (U)		19. SECURITY CLASSIFICATION OF ABSTRACT (U)	
				20. LIMITATION OF ABSTRACT (U)	

Grant No. AFOSR-89-0318

EQUIPMENT SUPPORT GRANT FOR AIR FORCE TASK
"CHEMICAL DEFENSE DRUGS EFFECTS WITH EXERCISE
AND THERMAL STRESS (HBCU)"

Reynaldo S. Elizondo, Ph.D.

The University of Texas at El Paso
El Paso, Texas 79968-0509

October 90

Final Report for Period May 1989 - May 1990

Prepared for

AFOSR/NL
Building 410
Bolling Air Force Grant
Washington, D.C. 20332-6448

ABSTRACT

The Equipment Support Grant, AFOSR-89-0318, provided the funds for the acquisition at The University of Texas at El Paso of a Nor-Lake Enviro-line Walk-in Climatic Chamber (6' long, 8' wide and 9' high) at a cost of \$10,809.00. The freight charges were \$977.00. The grant also provided resources for the renovation of laboratory space and installation costs totalling \$8214.00. The acquisition and installation of the above equipment supported a series of studies designed to quantitate the effects of neuroactive agents such as atropine and pyridostigmine on numerous physiological and performance parameters in a primate animal model which could not be carried out without the equipment support from this grant.

Specifically, The effects of a single intramuscular atropine injection (0.03 mg/kg) at ambient temperatures (Ta) of 25°C and 35°C and pyridostigmine treatment [5 doses (0.4 mg/kg)] at Ta of 35°C on the thermoregulatory capacity and exercise tolerance time of patas monkeys were investigated. A primate treadmill device was developed and used to evaluate the effects of the drugs on the exercise tolerance time. Rectal temperature (Tre) and heart rate (HR) were continuously monitored by a telemetry system while water loss was estimated from weight differences before and after exercise. Atropine effects were more pronounced at Ta of 35°C as indicated by a significant reduction in water loss (43%) which was associated with an average exercise time of 65 min less than the control value. The final HR and Tre responses in these atropine experiments were significantly elevated above the control values. Pyridostigmine significantly increased water loss (61%) which was associated with an average exercise time of 60 min longer than the control value. The final HR and Tre responses were not significantly affected by the pyridostigmine treatment.



Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

**EQUIPMENT SUPPORT GRANT FOR AIR FORCE TASK
"CHEMICAL DEFENSE DRUGS EFFECTS WITH EXERCISE AND THERMAL STRESS
(HBCU)"**

INTRODUCTION

Atropine, the most common antidote for anticholinesterase poisoning (13), suppresses thermoregulatory sweating, and eventually, evaporative heat loss through its anticholinergic activity (2) resulting in increased net heat storage (1, 15), decreased heat tolerance, and reduced exercise performance (4, 6, 7, 9).

Pyridostigmine is used in conjunction with atropine as a prophylactic against anticholinesterase poisoning by reversibly inhibiting cholinesterase. Depending on the degree of enzyme inhibition and state of ordination, these drugs affect thermoregulation and exercise performance in a negative (11) or positive way (12).

In a previous study, the physiological effects of 2 neurogenic drugs, atropine and pyridostigmine, on the thermoregulatory effector system of the patas monkeys were evaluated at rest. It was concluded that this species was an appropriate animal model to study the effects of neuroactive drugs on temperature regulation and thermoregulatory capacity (1, 10). This equipment support grant provided the acquisition and installation of a Nor-Lake Climatic Chamber to study the effects of atropine and pyridostigmine on the thermoregulatory capacity of patas monkeys during exercise in the heat. Prolonged exercise in the heat represents a condition where the metabolic and environmental heat load may be considerable and provides the body with maximum strain to challenge the thermoregulatory control system. Since atropine and pyridostigmine interfere with the heat dissipation mechanisms, the testing of these neuroactive agents during prolonged exercise in the heat provides maximum challenge to the thermoregulatory system and gives information about the thermoregulatory capacity of primates, and perhaps, man.

METHODS AND MATERIALS

Design of the Exercise Device

The apparatus used to evaluate the exercise tolerance of the patas monkey was a treadmill wheel (Fig. 1) specifically constructed to exercise nonhuman primates (8) (Appendix). The wheel, consisting of two 122-cm (48 in.) diameter Lucite rings and 120 aluminum bars, forms a circular cage which rotated freely on four bearings. Another ring, affixed to the outside of each Lucite ring, was connected to alternate aluminum bars to provide electrical stimulation for conditioning the animal. The activity

wheel included: 1) a magnetic tachometer pickup to quantitate speed; 2) an automatic control panel interconnected with the tachometer to allow the setting of upper and lower speed limits which the animal had to maintain in order to avoid a sequence of visual or electrical stimuli; 3) a microswitch at the bottom of the control panel which counted each revolution of the wheel and calculated distance traveled; and 4) a brake to stabilize the wheel during the rest periods as well as to prevent the animal from operating the wheel at higher than predetermined rates.

Exercise Program Operation

Five patas monkeys were trained to operate the treadmill wheel until they learned to run at a minimum rate of 2 miles/hour (mph) for 60 min (20).

At the end of a 20-week training period, each animal was capable of completing at least 1 h of exercise while control values of exercising heart rate (HR) and rectal temperature (Tre) were measured every 15 min by a noninvasive telemetry system. The system consisted of an AMF Quantum XL transmitter for measuring the HR and a Mini-Mitter rectal probe transmitter for measuring Tre. HR was recorded by an AMF Quantum digital watch receiver in beats/min (bpm) while Tre was recorded by a President AX52 FM receiver and converted to °C using calibration curves validated in this laboratory. Total distance covered in miles, average speed in miles/hour, and total exercise time were also recorded. Water loss was estimated from weight difference measured before and after the exercise test.

The criteria used to establish the exercise tolerance of the animals and to terminate the standard exercise test were any one of the following: heart rates that approach maximal heart rates for this species, approximately 300 bpm; a Tre higher than 40 °C to protect the animals from heat injury; or going 3 times underspeed (2 mph) in each of 2 consecutive 15-min periods.

The standard exercise tests were then repeated following atropine treatment and 3 months later after pyridostigmine treatment.

Two days after each animal completed a standard exercise test at 25 °C, another exercise test was carried out immediately following a .03 mg/kg single intramuscular (i.m.) atropine injection; a dose capable of establishing blood levels of atropine analogous to that produced in humans following an i.m. injection of 2 mg (14, 17). The same procedure was repeated 3 days later at 35 °C.

Pyridostigmine Study

One day after a standard exercise test was carried out at 35 °C, each animal was treated orally with 3 separate doses of




Figure 1. Primate Exercise Wheel (PEW).

solid 0.4 mg/kg pyridostigmine in a piece of banana. The afternoon of the next day, the animal repeated the exercise test after receiving 2 doses of 0.4 mg/kg pyridostigmine; 1 in the morning and 1 an hour prior to exercise, making a total of 5 doses. The 0.4 mg/kg pyridostigmine dosage is capable of reducing cholinesterase plasma levels by 25 to 30% of normal immediately after the second dose and keeps the levels down throughout the treatment period (1).

Treatment of Data

The results are presented as means and standard deviation. They were analyzed by a two-way (condition x time) analysis of variance (ANOVA) with repeated measures on both factors. Turkey's test of critical differences was also used where appropriate. All significant differences are reported at $p < .05$, unless otherwise noted.

RESULTS

The effects of atropine at 25 °C are shown in Table 1 and Figures 2 and 3.

TABLE 1. SUMMARY OF ATROPINE RESULTS DURING EXERCISE AT 25 °C AND 35 °C

	Water loss (g/min)	Time (min)	Distance (mi)	Speed (mph)
<hr/>				
Ta = 25 °C				
Control	1.2 ±1.7	177.0 ±39.7	4.8 ±1.2	1.6 ±0.05
Atropine	1.3 ±1.6	146.8* ±30.5	4.0 ±0.9	1.6 ±0.1
<hr/>				
Ta = 35 °C				
Control	2.3 ±2.1	149.6 ±37.1	3.6 ±0.8	1.5 ±0.1
Atropine	1.8 ^(t) ±2.3	84.0 ^(t) ±16.9	2.5 ^(t) ±0.5	1.7* ±0.1
<hr/>				

* $p < .05$

^(t) $p < .08$

Atropine significantly increased fatigue and shortened the exercise tolerance time by approximately 30 min. No significant difference was found in the amount of water loss, distance traveled or the animals' average speed. Figures 2 and 3 show that mean HR




Figure 2. Effects of atropine and exercise on heart rate at Ta of 25°C.
(* p<0.05 compared to no treatment)




Figure 3. Effects of atropine and exercise on rectal temperature at Ta of 25°C.
 (* p < 0.05 compared to no treatment)

and Tre responses increased from rest to exercise. While HR during exercise increased slightly over time in the control experiments, atropine administration caused a further increase in HR and was significantly greater at 60 min when compared to the no treatment condition. In addition, atropine was associated with a significant increase in Tre by the end of the first 30 min of exercise and remained 0.5 °C higher at 60 min of exercise, significantly different compared to the respective no treatment period. Mean final HR (F-HR) and Tre(F-Tre) values were not significantly different from the respective values in the control experiments.

The effects of atropine at 35 °C appear in Table 2 and Figures 4 and 5. At this environmental temperature, atropine produced a reduction in water loss rates (22%) and a reduction in total exercise time of 65 min less than the control value. Consequently, the distance covered in miles was also less ($p < .06$). It was also interesting that average speed in mph was slightly but significantly faster in the atropine experiments as compared to the controls. As illustrated in Figure 4, the mean HR response increased from rest to exercise and at the end of exercise. The mean HR response at 60 min of exercise decreased slightly from that at 30 min of exercise due to the fact that 2 animals reached their exercise tolerance before the first hour of exercise and only the mean HR response for 3 animals is shown. The mean HR response in the atropine experiments was higher at 60 min of exercise and before the end of exercise compared to the respective control experimental periods. Figure 5 shows the mean Tre responses in the heat continued to increase throughout the exercise time. However, atropine administration caused further increase in the rate of heat storage, compared to the respective no treatment exercise period.

Table 2 shows pyridostigmine treatment tended to increase water loss (11%) and was associated with an average exercise time of 61 min longer than the control value and consequently longer distance traveled in miles. Average speed in mph was slightly but significantly higher in the pyridostigmine experiments compared to the controls. Final heart rate (F-HR) and final Tre (F-Tre) responses were not significantly different from those in the control experiments.

TABLE 2. SUMMARY OF PYRIDOSTIGMINE EFFECTS DURING EXERCISE AT 35 °C

	R-HR	F-HR	R-Tre	F-Tre	Water Loss	Time	Distance	Speed
	(bpm)	(bpm)	(°C)	(°C)	(g/min)	(min)	(mi)	(mph)
Control	160.4 ±10.9	223.0 ±11.0	37.9 ±0.1	39.3 ±0.2	1.9 ±3.0	115.0 ±29.0	3.0 ±0.8	1.5 ±0.1
Pyrido- stigmine	160.6 ±10.7	214.2 ±11.8	37.7 ±0.2	39.0 ±0.3	2.1 ±3.0	175.0* ±29.0	5.0* ±0.9	1.7* ±0.1

* $p < .05$
R=Resting
F=Final




Figure 4. Effects of atropine and exercise on heart rate at Ta of 35°C.
(* p < 0.05 compared to no treatment)




Figure 5. Effects of atropine on rectal temperature during exercise at Ta of 25°C.
(* p < 0.05 compared to no treatment)

DISCUSSION

The results of these studies showed that the physiological effects of atropine in exercising patas monkeys were similar to those reported for humans. The suppressed sweating capacity of the atropine significantly affected the heat loss mechanisms of the exercising animals in the heat as indicated by the 43% reduction in water loss. On the contrary, during exercise at thermoneutral environment, the amount of water loss was not significantly different between the atropine and control experiments. During exercise, there is enhanced release of epinephrine by the adrenal medulla which accounts for increased sweating (24); a fact which at neutral environment seems to completely counteract the negative effects of atropine on sweating. The suppressed sweating induced by atropine generally resulted in increased heat storage causing considerable thermal strain on the animals. It is speculated to account for the reduced time that the animals could exercise. In addition, exercise in the heat caused much faster rise in the rate of heat storage on the animal's body with potentially greater performance decrements and increased risks for heat injuries. For instance, exercise in the heat, for all animals but one, was terminated by the investigator when the T_{re} was in excess of 40 °C. Conversely, at the thermoneutral environment, the animals took longer to reach exercise tolerance. The time that elapsed between the first signs of discomfort and the time they reached the criteria for termination of exercise (see Methods and Materials) was also much longer. At this environmental temperature, all animals but one were stopped from exercising because they fulfilled the criterion concerning the speed limit that should be sustained. Although mean $F-T_{re}$ response at 25 °C was not significantly different in the control and atropine exercise experiments, these data revealed that animals with low exercise tolerance (exercise time < 2.30 h) demonstrated much higher $F-T_{re}$ values in the atropine experiments (40.2 °C vs control value of 39.5 °C). This may have to do with the pharmacokinetics of atropine in the plasma (half-life 2.5 h) and the fact that the exercise time of the animals varied between 1.30 and 5.0 hours.

Mahoney (22) investigated the response of a single patas monkey while running in the heat and reported that at any given temperature the onset of exercise caused a threefold increase in conductance regardless of the particular speed. Some of this increase could be associated with increased blood flow to the working muscles and previous work from this laboratory in resting animals showed that atropine induced peripheral vasodilation as indicated by increased whole-body conductance (1). Similar increases in conductance were also found in exercising human subjects after atropine (9, 19). Therefore, it was speculated that increased blood pooling in the periphery to compensate for the decreased heat dissipation from sweating would have aggravated the problem by compromising blood flow to the exercising muscles and would have reduced their exercise capacity.

Although atropine blood levels were not measured in this study, results show that the time course for the physiological effects of atropine on heart rate and heat loss mechanisms, as indicated by increase in Tre, was between 30 to 60 min post-injection. This finding agrees with the results found by other investigators involving a variety of atropine dosages injected in human subjects (5, 6, 21, 23, 25). Furthermore, Craig (4) reported that 2 mg of atropine, a dose analogous to the one administered in the present study, resulted in nearly maximal vagal inhibition. In this study, mean final heart rate increased by 16 bpm and mean final rectal temperature increased by 0.7 °C under the influence of atropine during exercise in the heat. Various results, concerning the amount of increase in HR and Tre, have been found in human studies (4, 21, 25). Direct comparisons between the studies are tenuous because of differences in environmental conditions, subject variability, exercise mode, and protocols used.

The effects of pyridostigmine treatment have been reported in rats but not in primates. Francesconi et al. (11) reported that in rats, pharmacological acute doses of pyridostigmine greatly affected exercise performance, thermoregulation, and chemical indices of heat/exercise injury following 64% cholinesterase inhibition. In another study, Francesconi et al. (12) reported that moderate cholinesterase inhibition of 23% and 39% attenuated several of the acute responses and had no debilitating effects on physical performance and thermoregulation during exercise in the heat. They reached the conclusion that a rather narrow range of cholinesterase inhibition must be achieved before the physiological and protective effects of pyridostigmine are observed. Their findings agree with the results found in this study. We found that oral administration of 0.4 mg/kg pyridostigmine improved thermoregulatory function and was associated with a 60 min longer average exercise time than the control value.

REFERENCES

1. Avlonitou, E., and Elizondo, R. S. Effects of atropine and pyridostigmine in heat-stressed patas monkeys. *Aviat Space Environ Med* 59:544-548 (1988).
2. Batra, G., Traystman, R., Rudnick, H., and Menkes, H. Effects of body position and cholinergic blockade on mechanisms of collateral ventilation. *J Appl Physiol* 50:358-360 (1981).
3. Brown, E. Analysis of gaseous exchange in open circuit calorimetry. *Medical Biological Engineering and Computing*. 22:333-338 (1984).
4. Craig, F. N. Effects of atropine, work and heat on heart rate and sweat production in man. *J Appl Physiol* 4:309-319 (1952).
5. Craig, F. N., and Cummings, E. Dehydration and muscular work. *J Appl Physiol* 21:670-674 (1966).
6. Cullumbine, H., McKee, W. H. E., and Creasey, N. H. The effects of atropine sulfate upon healthy male subjects. *Q J Exp Physiol* 40:309-319 (1955).
7. Cullumbine, H., and Miles, S. The effects of atropine sulfate on men exposed to warm environments. *Q J Exp Physiol* 41:162-179 (1956).
8. Curran, C. R., Wiegel, W. R., and Stevens, D. N. Design and operation of an exercise device for subhuman primates. *Armed Forces Radiology Research Institute TN 72-1 Defense Nuclear Agency*. Bethesda, MD (1972).
9. Davies, C. T. M., Brotherhood, J. R., and Zeidiford, E. Effects of atropine and beta blockade on temperature regulation and performance during prolonged exercise. *Eur J Appl Physiol* 38:225-232 (1978).
10. Elizondo, R., Primate models to study sweating. *Am J Primatology* 14:265-276 (1988).
11. Francesconi, R., Hubbard, R., and Mager, M. Effects of pyridostigmine on ability of rats to work in the heat. *J Appl Physiol* 45(4):891-895 (1984).
12. Francesconi, R., Hubbard, R., Matthew, C., Leva N., Young J., and Pease, V. Oral pyridostigmine administration in rats: Effects on thermoregulation, clinical chemistry, and performance in the heat. *Pharmacol Biochem Behav* 25:1071-1075 (1986).

13. Gisolfi, C. F., Sato, K., Wall, P. T., and Sato, F. In vivo and in vitro characteristics of eccrine sweating in patas and rhesus monkeys. *J Appl Physiol* 56 (3): 425-431 (1982).
14. Harris, L. W., Stitcher, D. L., Heyl, W. C., Lieske C. N., Lowe, G. R., and Clark, J. H., Broomfield, CA. The effects of atropine-oximetherapy on cholinesterase activity and survival on animals intoxicated with p-nitrodiphenyl-d-n-butylphosphinate. *Toxicol Appl Pharmacol* 49:23-9 (1979).
15. Hubbard, R. W., Matthew, C. B., and Francesconi, R. Heat stressed rat: Effects of atropine, desalivation or restraint. *J Appl Physiol* 53:1171-1174 (1982).
16. Johnson, G. S., and Elizondo, R. S. Temperature regulation in Macaca mulatta: A thermal balance study. *J Appl Physiol* 46: 268-277 (1979).
17. Kalser, S. C., and McLain, P. L. Atropine metabolism in man. *Clin Pharmacol Ther* 11:214-227 (1970).
18. Kolka, M. A., and Elizondo, R. S. Thermoregulation in Erythrocebus patas: A thermal balance study. *J Appl Physiol* 55(5):16303-16308 (1983).
19. Kolka, M. A., and Stephenson, L. A. Cutaneous blood flow and local sweating after systemic atropine administration. *Pflugere Arch* 410:524-529 (1987).
20. Kramsch, D. M., Aspen, A. S., Abramowitz, B. M., Kreimendahl, T., and Hood, W. B. Reduction of coronary atherosclerosis by moderate conditioning exercise in monkeys on an atherogenic diet. *N Engl J Med* 305(25):1483-1489 (1981).
21. Levine, L., Sawka, M. N., Joyce, B. E., Cadarette, B. S., and Pandolf, K. B. Varied and repeated atropine dosages and exercise heat stress. *Eur J Appl Physiol* 53(1):12-16 (1984).
22. Mahoney, S. A. Cost of locomotion and heat balance during rest and running from 0° to 55°C in a patas monkey. *J Appl Physiol* 49:788-800 (1980).
23. Mirakhur, R. K. Comparative study of the effects of oral and i.m. atropine and hyoscine in volunteers. *Br J Anaesth* 50: 591-198 (1987).
24. Robertshaw, D., Taylor, C. R., and Mazzia, L. M. Sweating in primates: Secretion by the adrenal medulla during exercise. *Ama J Physiol* 224:678-681 (1973).

25. Sawka, M. N., Levine, L., Kolka, M. A., Appleton, B. S., Joyce, B. E., and Pandolf, K. B. Effects of atropine on the exercise - heat performance of man. Fundam Appl Toxicol 4:S190-S-194 (1984).